Marine Polymer Technologies, Inc.

Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and manufactures advanced biomaterials designed for hemostasis, wound healing, and the control of severe bleeding. The company's core technology utilizes unique poly-N-acetyl glucosamine (pGlcNAc) fibers derived from microalgae. These fibers work through biological mechanisms that include promoting red blood cell agglutination, platelet activation, and thrombin generation to form stable hemostatic plugs, as well as accelerating wound closure through re-epithelialization and increased cell migration. MPT's product line includes SyvekExcel, designed for hemostasis during vascular catheterization; Talymed, an advanced wound-care product for managing chronic wounds like diabetic and venous leg ulcers; and mrdh, intended for the rapid control of severe arterial and venous bleeding.

These solutions are engineered to support healthcare providers by offering reliable, efficient, and safe alternatives to conventional therapies, even for patients who are clinically coagulopathic. By eliminating the need for prep time, special storage, or complex reagent mixing, MPT's products aim to improve clinical workflows and patient outcomes in both surgical and emergency settings. The efficacy of the company's pGlcNAc technology has been validated in various clinical trials and documented in professional medical literature. MPT, founded in 1992, maintains a commitment to rigorous research and development, ensuring its medical devices comply with FDA regulatory standards while addressing significant challenges in patient care and trauma management.